Since we observed that pre-existing NGFRhi tumor cells could expand selectively on T cell pressure, and because we observed that those expanded fractions are resistant to BRAF + MEKi, we then tested whether this cross-resistance phenomenon also occurred in vivo. Here, BRAF is linked to neoplasm.